Related Experiment Videos
Evidence for "response to injury" hypothesis
Life Sciences
|December 6, 1982
Summary
Platelet-derived growth factor (PDGF) drives myointimal thickening after artery injury. The PDGF antagonist trapidil effectively inhibited this thickening in rat models, suggesting a potential therapeutic approach for atherosclerosis.
Area of Science:
- Vascular biology
- Pharmacology
- Cardiovascular research
Background:
- The
- response to injury
- hypothesis proposes that vascular smooth muscle cell proliferation contributes to intimal thickening after arterial injury.
- Platelet-derived growth factor (PDGF) is a key mediator implicated in this process.
Purpose of the Study:
- To investigate the role of PDGF in myointimal thickening following arterial injury.
- To evaluate the efficacy of trapidil, a PDGF antagonist, in preventing or reducing this thickening.
Main Methods:
- Experiments were conducted using cultured rat carotid artery rings and in vivo models of air-injured rat arteries.
- PDGF-induced cell growth in denuded arterial rings was assessed.
- Thrombocytopenic rats received PDGF injections, and myointimal thickening was measured after air injury.
- Trapidil was administered orally to assess its inhibitory effects on PDGF-induced and injury-induced myointimal thickening in normal and hypertensive rats.
Main Results:
- PDGF promoted cell growth in denuded but not intact cultured arterial rings.
- Systemic PDGF administration in thrombocytopenic rats led to significant myointimal thickening after air injury.
- Trapidil administration effectively inhibited PDGF-induced cell growth in vitro.
- Oral trapidil significantly reduced myointimal thickening in vivo in both thrombocytopenic and normal rats, including hypertensive models.
Conclusions:
- These findings provide strong evidence for the critical role of PDGF in mediating myointimal thickening, supporting the
- response to injury
- hypothesis.
- Trapidil demonstrates significant potential as a therapeutic agent for treating atherosclerosis by targeting PDGF-mediated vascular remodeling.